Online tool tracks COVID-19 vaccine development
A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University of Notre Dame Center for Research Computing. Read More
CordenPharma to provide excipients for Moderna's vaccine candidate
A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273. Read More
Italian study links social isolation to elderly COVID-19 cases
A new study of COVID-19 infections in Italy suggests that factors associated with social isolation help explain why Italy's large senior population has been disproportionately affected by the COVID-19 pandemic. The findings were published May 21 in the journal PLOS One. Read More
Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19. Read More
Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp up a variety of biologics. The strong demand for bioprocessed medicines in 2020 will continue to drive growth of the industry. Read More
Merck to acquire Themis for SARS-CoV-2 vaccine
Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2. Read More
Merck, Ridgeback Bio partner on COVID-19 antiviral
Merck and Ridgeback Biotherapeutics announced that they have entered a collaboration to develop EIDD-2801, an orally available antiviral candidate in early clinical development for treatment of patients with COVID-19. Read More
IAVI, Merck partner on SARS-CoV-2 vaccine
Merck and IAVI, a nonprofit scientific research organization, announced that they are partnering to develop a recombinant vesicular stomatitis virus vaccine candidate against SARS-CoV-2. Read More
AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets. Read More
Sinovac receives $15M for COVID-19 vaccine
Biopharmaceutical company Sinovac Biotech announced that Advantech Capital and Vivo Capital invested $15 million in the firm's research and development company, Sinovac Research and Development, to create an inactivated vaccine against COVID-19. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter